--- title: "Perrigo | 10-Q: FY2026 Q1 Revenue Misses Estimate at USD 969.2 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/285432582.md" datetime: "2026-05-06T20:26:05.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285432582.md) - [en](https://longbridge.com/en/news/285432582.md) - [zh-HK](https://longbridge.com/zh-HK/news/285432582.md) --- # Perrigo | 10-Q: FY2026 Q1 Revenue Misses Estimate at USD 969.2 M Revenue: As of FY2026 Q1, the actual value is USD 969.2 M, missing the estimate of USD 1.035 B. EPS: As of FY2026 Q1, the actual value is USD -2.87, missing the estimate of USD 0.33. EBIT: As of FY2026 Q1, the actual value is USD -367.7 M. #### Consolidated Financial Performance Net sales for the three months ended March 28, 2026, were $969.2 million, a decrease from $1,043.9 million in the prior year period. Gross profit was $325.5 million (33.6% of net sales) for the current period, down from $392.3 million (37.6% of net sales) in the prior year. The company reported an operating loss of - $372.3 million (-38.4% of net sales) for the three months ended March 28, 2026, compared to an operating income of $46.9 million (4.5% of net sales) in the prior year. Net loss for the period was - $398.6 million, compared to a net loss of - $6.4 million in the prior year. #### Segment Revenue - **Self Care:** Net sales decreased by 11.5% to $543.3 million for the three months ended March 28, 2026, from $614.3 million in the prior year, primarily due to an $85.8 million decrease from lower consumption in the U.S. and Europe, partly offset by a $16.9 million increase from favorable foreign currency translation. - **Specialty Care:** Net sales increased by 4.0% to $207.0 million for the three months ended March 28, 2026, from $199.1 million in the prior year, mainly driven by a $9.5 million increase from favorable foreign currency translation, partially offset by a $1.7 million decrease in Skin Health. - **Infant Formula:** Net sales increased by 2.1% to $89.7 million for the three months ended March 28, 2026, from $87.8 million in the prior year, primarily due to a $1.6 million increase from growth in contract infant formula. - **All Other:** Net sales decreased by 9.5% to $129.2 million for the three months ended March 28, 2026, from $142.7 million in the prior year, mainly due to a $16.9 million decrease from lower net sales of Oral Care products, partially offset by a $3.4 million increase from favorable foreign currency translation. #### Segment Operating Income (Loss) and Margin - **Self Care:** Segment operating income decreased by 39.3% to $68.5 million (12.6% operating margin) for the three months ended March 28, 2026, from $112.8 million (18.4% operating margin) in the prior year. - **Specialty Care:** Segment operating income increased by 31.4% to $55.3 million (26.7% operating margin) for the three months ended March 28, 2026, from $42.1 million (21.1% operating margin) in the prior year. - **Infant Formula:** Segment operating income was - $7.4 million (-8.3% operating margin) for the three months ended March 28, 2026, compared to $10.6 million (12.1% operating margin) in the prior year. - **All Other:** Segment operating income increased by 52.1% to $31.9 million (24.7% operating margin) for the three months ended March 28, 2026, from $21.0 million (14.7% operating margin) in the prior year. #### Cash Flow - **Net cash for operating activities:** - $113.6 million for the three months ended March 28, 2026, a decrease from - $64.5 million in the prior year. - **Net cash for investing activities:** - $12.4 million for the three months ended March 28, 2026, an increase from - $25.7 million in the prior year. - **Net cash for financing activities:** - $45.3 million for the three months ended March 28, 2026, an increase from - $61.8 million in the prior year. - **Net decrease in cash and cash equivalents:** - $174.4 million for the three months ended March 28, 2026, compared to - $141.7 million in the prior year. #### Other Key Financial Metrics - **Impairment Charges:** The company recorded goodwill impairment charges totaling $330.8 million for the three months ended March 28, 2026, including $77.4 million for Women’s Health, $66.3 million for Infant Formula, and $187.2 million for Oral Care, compared to $3.1 million in the prior year. - **Restructuring Charges:** Total restructuring charges were $75.1 million for the three months ended March 28, 2026, compared to $29.4 million in the prior year, primarily associated with the Operational Enhancement Program ($73.1 million), Nutrition Network Optimization ($2.2 million), and Supply Chain Reinvention ($0.1 million). - **Inventory:** Total inventory was $1,121.4 million as of March 28, 2026, down from $1,149.0 million as of December 31, 2025. - **Depreciation:** Total depreciation expense was $28.9 million for the three months ended March 28, 2026, up from $24.9 million in the prior year. - **Interest Expense, net:** $40.8 million for the three months ended March 28, 2026, compared to $39.0 million in the prior year. - **Other (income), net:** - $6.0 million for the three months ended March 28, 2026, compared to - $0.4 million in the prior year. - **Loss on extinguishment of debt:** $1.4 million for the three months ended March 28, 2026. #### Future Outlook and Strategy Perrigo Company plc is focused on its vision to provide self-care solutions accessible to all, aiming for sustainable and value-accretive growth through delivering consumer-preferred brands, driving category growth with customers, strengthening its global supply chain, and evolving its organizational model. The company’s ‘Three-S’ plan (Stabilizing, Streamlining, Strengthening) is central to increasing cash flow and total shareholder return by restoring core business consistency, streamlining costs, and building scalable growth capabilities. Recent initiatives include the Operational Enhancement Program, expected to yield $80 million to $100 million in gross pre-tax annual run rate cost savings primarily in 2026, and a strategic review of its Infant Formula business to accelerate cash flows and optimize portfolio impact, following the sale of its Dermacosmetics Business for up to €332.6 million. ### Related Stocks - [PRGO.US](https://longbridge.com/en/quote/PRGO.US.md) ## Related News & Research - [Infant Formula Probes And ESOP Share Filing Might Change The Case For Investing In Perrigo (PRGO)](https://longbridge.com/en/news/285354387.md) - [Examining options for FX hedging](https://longbridge.com/en/news/286789264.md) - [DaVita Sets Bold 2030 Community Care Commitments After Exceeding Prior Five-Year ESG Goals | DVA Stock News](https://longbridge.com/en/news/286808813.md) - [How to Read the COT Report to Track Forex Market Sentiment](https://longbridge.com/en/news/286848676.md) - [13:39 ETRodeo Dental & Orthodontics Expands Access to Affordable, Quality Dental Care in Glendale](https://longbridge.com/en/news/286804016.md)